Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis.

Frontiers in endocrinology · January 2026 · Asad Omarion, Yaman Ayasa, Zainab Omarion, Batoul Jayouse, Hazem Ayesh

What this study found

GLP-1 receptor agonists combined with metformin appear to be the most effective pharmacologic therapies for anthropometric improvement, specifically body weight and BMI reduction, in women with PCOS. These conclusions are limited to anthropometric and metabolic parameters, reproductive, endocrine, and patient-centered…

Open on PubMed DOI

systematic_review

How RAGMD uses this study

Clinical questions this paper informs

Synthesis lives on the evidence question — this page shows where the study sits in that analysis.

Core study

What is the evidence for hormone and metabolic therapy in PCOS?

PCOS management prioritizes lifestyle intervention, cycle regulation, and treatment of hyperandrogenism and metabolic risk. Metformin and hormonal contraceptives have evidence for specific endpoints; individualized plans depend on fertility goals.

Open evidence analysis

Read the evidence analysis Research library